Skip to main content
. Author manuscript; available in PMC: 2018 Mar 27.
Published in final edited form as: Neuroscience. 2017 Jan 23;346:349–364. doi: 10.1016/j.neuroscience.2017.01.021

Fig. 2.

Fig. 2

Effect of HZ166 on the VMR to CRD of neonatal saline- and zymosan-treated rats tested at P60. (A) Neonatal zymosan-treated rats exhibited visceral hypersensitivity characterized by significantly (n=6, p<0.001 vs neonatal saline- treated rats) increased VMR to CRD from 10 mmHg onwards. (B) Administration of HZ166 (10 μg/animal, i.t) to neonatal saline- treated rats produced a significant (n=6, p<0.001 vs pre-HZ166) decrease in their VMR to graded CRD from distension pressure 30 mmHg onwards. (C) However, in neonatal zymosan-treated rats, the same dose of HZ166 did not produce any inhibition of the VMR to CRD. Values expressed as mean ± S.E.M of ‘6’ animals in each group. p≤0.05 was considered significant. * compared with neonatal saline-treated or pre-HZ166 baseline.